Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Nikolay V Kislov"'
Autor:
Liudmila G. Zhukova, Larisa V. Bolotina, Victoria V. Dvornichenko, Natalia V. Fadeeva, Inna P. Ganshina, Katerina S. Grechukhina, Alfiya I. Hasanova, Nikolay V. Kislov, Igor Yu. Kudryavtsev, Alexey G. Manikhas, Natalia E. Musaeva, Alexandra A. Nizhegorodtseva, Olga E. Sadikova, Dina D. Sakaeva, Anton V. Snegovoy, Daniil L. Stroyakovskiy, Sergei A. Tjulandin, Ekaterina A. Trishkina, Liubov Iu. Vladimirova, Nikita M. Volkov, Yulia V. Kostalanova
Publikováno v:
Современная онкология, Vol 26, Iss 1, Pp 56-64 (2024)
Background. The use of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors in combination with endocrine therapy is a key initial treatment for advanced luminal HER2-negative (HR+/HER2-) breast cancer. The approval studies MONALEESA-2 and 7 demonstra
Externí odkaz:
https://doaj.org/article/38d513dc74f248e7bd74c0e83c57a19a
Autor:
Xavier Pivot, Mark D Pegram, Javier Cortes, Diana Lüftner, Gary H Lyman, Giuseppe Curigliano, Igor M Bondarenko, Mikhail Dvorkin, Jin Hee Ahn, Seock-Ah Im, Maria Litwiniuk, Yaroslav V Shparyk, Gwo Fuang Ho, Nikolay V Kislov, Marek Wojtukiewicz, Tomasz Sarosiek, Yee Soo Chae, Jin Seok Ahn, Hyerin Jang, Sujung Kim, Jiwon Lee, Soo Young Lee, Ye Chan Yoon
Publikováno v:
Cancer Research. 82:P2-13
Background: SB3 (trastuzumab-dttb) is a biosimilar approved globally based on its similarity with reference trastuzumab (TRZ) demonstrated by thorough comparability exercises in analytical, biological, and clinical studies. In a randomized, double-bl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8ac9d7475f9c956820aba3a825a77e9d
https://doi.org/10.1158/1538-7445.sabcs21-p2-13-04
https://doi.org/10.1158/1538-7445.sabcs21-p2-13-04
Autor:
Xavier Pivot, Javier Cortés, Diana Lüftner, Gary H. Lyman, Giuseppe Curigliano, Igor M. Bondarenko, Jin-Hee Ahn, Seock-Ah Im, Maria Litwiniuk, Yaroslav V. Shparyk, Gwo Fuang Ho, Nikolay V. Kislov, Marek Wojtukiewicz, Tomasz Sarosiek, Yee Soo Chae, Jin Seok Ahn, Hyerin Jang, Sujung Kim, Jiwon Lee, YeChan Yoon
Publikováno v:
JAMA Network Open. 6:e235822
ImportanceTrastuzumab has been the standard of care for the treatment of patients with ERBB2-positive breast cancer; however, cardiac events have been reported. This long-term follow-up study provides clinical evidence supporting the similarity of a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eabdffb78b6065dad24b6ad0af425f85
https://doi.org/10.1001/jamanetworkopen.2023.5822
https://doi.org/10.1001/jamanetworkopen.2023.5822